FLT PET for non-invasive monitoring of early response to gene therapy in experimental gliomas

Molecular Imaging and Biology

Volumn 13, Issue 3, 2011, Pages 547-557

  Rueger, Maria A ^a,b,c   Ameli, Mitra ^a,c   Li, Hongfeng ^a   Winkeler, Alexandra ^a,b   Rueckriem, Benedikt ^c   Vollmar, Stefan ^a   Galldiks, Norbert ^a   Hesselmann, Volker ^c   Fraefel, Cornel ^a   Wienhard, Klaus ^a   Heiss, Wolf Dieter ^a   Jacobs, Andreas H ^a,b,d  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

18F FLT PET; Glioma; HSV 1 tk; Suicide gene therapy

Indexed keywords

3' FLUOROTHYMIDINE F 18; 9 (4 FLUORO 3 HYDROXYMETHYLBUTYL)GUANINE F 18; CYTOSINE DEAMINASE; FLUCYTOSINE; GANCICLOVIR; PLACEBO; RADIOPHARMACEUTICAL AGENT; THYMIDINE KINASE; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; GREEN FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; ESCHERICHIA COLI; GENE EXPRESSION; GLIOMA; GLIOMA CELL; HERPES SIMPLEX VIRUS 1; MOUSE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SUICIDE GENE THERAPY; TREATMENT RESPONSE; TUMOR REGRESSION; ANIMAL; CELL PROLIFERATION; DRUG SCREENING; GENE THERAPY; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; SCINTISCANNING; TIME; TREATMENT OUTCOME; TUMOR CELL LINE;

HUMAN HERPESVIRUS 1; MUS MUSCULUS;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; GENE EXPRESSION; GENE THERAPY; GLIOMA; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956197876     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0361-6     Document Type: Article

References (40)

1. Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system (WHO). International Agency for Research on Cancer (IARC), Lyon
2. Preston-Martin S (1999) Epidemiology. In: Berger MS, Wilson CD (eds) The gliomas. Saunders, Philadelphia, pp 2-11
3. MC de Wit HG de Bruin W Eijkenboom PA Sillevis Smitt MJ van den Bent 2004 Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression Neurology 63 535 537 15304589 (Pubitemid 39031388)
4. AJ Kumar NE Leeds GN Fuller P Van Tassel MH Maor RE Sawaya, et al. 2000 Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment Radiology 217 377 384 11058631 1:STN:280:DC%2BD3crhtFeqsg%3D%3D
5. AF Shields JR Grierson BM Dohmen HJ Machulla JC Stayanoff JM Lawhorn-Crews, et al. 1998 Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat Med 4 1334 1336 9809561 10.1038/3337 1:CAS:528:DyaK1cXntlaqsrk%3D (Pubitemid 28512118)
6. AK Buck H Schirrmeister M Hetzel HM Von Der G Halter G Glatting, et al. 2002 3-Deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules Cancer Res 62 3331 3334 12067968 1:CAS:528:DC%2BD38XkslWqs7k%3D (Pubitemid 34651372)
7. DC Cobben PL Jager PH Elsinga B Maas AJ Suurmeijer HJ Hoekstra 2003 3′-18F-Fluoro-3′-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? J Nucl Med 44 1927 1932 14660718 1:CAS:528: DC%2BD2cXjt1Sgtg%3D%3D (Pubitemid 40022138)
8. DL Francis D Visvikis DC Costa TH Arulampalam C Townsend SK Luthra, et al. 2003 Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer Eur J Nucl Med Mol Imaging 30 988 994 12739071 10.1007/s00259-003-1187-0 1:CAS:528:DC%2BD3sXlvFaqtbw%3D (Pubitemid 37086941)
9. M Wagner U Seitz A Buck B Neumaier S Schultheiss M Bangerter, et al. 2003 3′-[18F]Fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease Cancer Res 63 2681 2687 12750297 1:CAS:528: DC%2BD3sXjslehtLw%3D (Pubitemid 36605213)
10. W Chen T Cloughesy N Kamdar N Satyamurthy M Bergsneider L Liau, et al. 2005 Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG J Nucl Med 46 945 952 15937304 1:CAS:528:DC%2BD28XitFSqtrw%3D (Pubitemid 43733508)
11. SJ Choi JS Kim JH Kim SJ Oh JG Lee CJ Kim, et al. 2005 [(18)F]3′-Deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors Eur J Nucl Med Mol Imaging 32 653 659 15711980 10.1007/s00259-004-1742-3 (Pubitemid 40897487)
12. AH Jacobs A Thomas LW Kracht H Li C Dittmar G Garlip, et al. 2005 18F-Fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors J Nucl Med 46 1948 1958 16330557 1:CAS:528:DC%2BD28XivVSktA%3D%3D (Pubitemid 46657440)
13. MS Bradbury D Hambardzumyan PB Zanzonico J Schwartz S Cai EM Burnazi, et al. 2008 Dynamic small-animal PET imaging of tumor proliferation with 3′-deoxy-3′-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas J Nucl Med 49 422 429 18287265 10.2967/jnumed.107. 047092 (Pubitemid 351355208)
14. R Ullrich H Backes H Li L Kracht H Miletic K Kesper, et al. 2008 Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma Clin Cancer Res 14 2049 2055 18381944 10.1158/1078-0432.CCR-07-1553 1:CAS:528:DC%2BD1cXkt1akurY%3D (Pubitemid 351551115)
15. AH Jacobs A Winkeler M Hartung M Slack C Dittmar C Kummer, et al. 2003 Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes Hum Gene Ther 14 277 297 12639307 10.1089/10430340360535823 1:CAS:528: DC%2BD3sXhsVGiu7c%3D (Pubitemid 36423446)
16. ME Black TG Newcomb HM Wilson LA Loeb 1996 Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy Proc Natl Acad Sci USA 93 3525 3529 8622970 10.1073/pnas.93.8.3525 1:CAS:528: DyaK28XisVWitLs%3D (Pubitemid 26125654)
17. HJ Machulla A Blocher M Kuntzsch M Piert R Wei JR Grierson 2000 Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F] fluorothymidine ([18F]FLT) J Radioanal Nucl Chem 243 843 846 10.1023/A:1010684101509 1:CAS:528:DC%2BD3cXjsVKlt7k%3D (Pubitemid 30462551)
18. C Wodarski J Eisenbarth K Weber M Henze U Haberkorn M Eisenhut 2000 Synthesis of 3-deoxy-3-[18F]fluoro-thymidine with 2, 3-anhydro-5-O-(4, 4-dimethoxytrityl)-thymidine J Label Compd Radiopharm 43 1211 1218 10.1002/1099-1344(20001030)43:12<1211::AID-JLCR408>3.0.CO;2-# 1:CAS:528:DC%2BD3cXns1Sht74%3D
19. J Cizek K Herholz S Vollmar R Schrader J Klein WD Heiss 2004 Fast and robust registration of PET and MR images of human brain Neuroimage 22 434 442 15110036 10.1016/j.neuroimage.2004.01.016 (Pubitemid 38515852)
20. K Herholz K Wienhard WD Heiss 1990 Validity of PET studies in brain tumors Cerebrovasc Brain Metab Rev 2 240 265 2121212 1:STN:280: DyaK3M%2Fis1yktw%3D%3D
21. AH Jacobs C Dittmar A Winkeler G Garlip WD Heiss 2002 Molecular imaging of gliomas Mol Imaging 1 309 335 12926228 10.1162/153535002321093936 1:CAS:528:DC%2BD3sXmsF2ksw%3D%3D
22. M Hengstschlager M Knofler EW Mullner E Ogris E Wintersberger E Wawra 1994 Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells J Biol Chem 269 13836 13842 8188661 1:STN:280:DyaK2c3ksFKqsQ%3D%3D (Pubitemid 24191128)
23. J Toyohara A Waki S Takamatsu Y Yonekura Y Magata Y Fujibayashi 2002 Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines Nucl Med Biol 29 281 287 11929696 10.1016/S0969- 8051(02)00286-X (Pubitemid 34258548)
24. JS Rasey JR Grierson LW Wiens PD Kolb JL Schwartz 2002 Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells J Nucl Med 43 1210 1217 12215561 1:CAS:528:DC%2BD38Xns1elsrk%3D (Pubitemid 34988769)
25. JL Schwartz Y Tamura R Jordan JR Grierson KA Krohn 2003 Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs J Nucl Med 44 2027 2032 14660729 1:CAS:528: DC%2BD2cXjt1SnsA%3D%3D (Pubitemid 40022149)
26. XB Kong QY Zhu PM Vidal KA Watanabe B Polsky D Armstrong, et al. 1992 Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′- deoxythymidine and 3′-azido-3′-deoxythymidine Antimicrob Agents Chemother 36 808 818 1503443 1:CAS:528:DyaK38XktVSgsLw%3D
27. W Chen S Delaloye DH Silverman C Geist J Czernin J Sayre, et al. 2007 Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol 25 4714 4721 17947718 10.1200/JCO.2006.10.5825 1:CAS:528:DC%2BD2sXhtlCgsLjL (Pubitemid 350086472)
28. H Dittmann BM Dohmen R Kehlbach G Bartusek M Pritzkow M Sarbia, et al. 2002 Early changes in [18F]FLT uptake after chemotherapy: an experimental study Eur J Nucl Med Mol Imaging 29 1462 1469 12397465 10.1007/s00259-002-0925-z 1:CAS:528:DC%2BD38XotV2isbY%3D (Pubitemid 35232048)
29. J Leyton JR Latigo M Perumal H Dhaliwal Q He EO Aboagye 2005 Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo Cancer Res 65 4202 4210 15899811 10.1158/0008-5472.CAN-04-4008 1:CAS:528:DC%2BD2MXktlSmtrs%3D (Pubitemid 40775658)
30. C Waldherr IK Mellinghoff C Tran BS Halpern N Rozengurt A Safaei, et al. 2005 Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET J Nucl Med 46 114 120 15632041 1:CAS:528:DC%2BD2MXhsVektrw%3D (Pubitemid 43086005)
31. NG Rainov 2000 A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme Hum Gene Ther 11 2389 2401 11096443 10.1089/104303400750038499 1:CAS:528:DC%2BD3cXosVGgt7g%3D
32. N Shand F Weber L Mariani M Bernstein A Gianella-Borradori Z Long, et al. 1999 A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group Hum Gene Ther 10 2325 2335 10515452 10.1089/10430349950016979 1:CAS:528:DyaK1MXmtlWquro%3D (Pubitemid 29459843)
33. AM Sandmair S Loimas P Puranen A Immonen M Kossila M Puranen, et al. 2000 Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses Hum Gene Ther 11 2197 2205 11084677 10.1089/104303400750035726 1:CAS:528:DC%2BD3cXnvVOgsb0%3D
34. TW Trask RP Trask E Aguilar-Cordova HD Shine PR Wyde JC Goodman, et al. 2000 Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors Mol Ther 1 195 203 10933931 10.1006/mthe.2000.0030 1:CAS:528:DC%2BD38XhvF2hs78%3D
35. JM Markert MD Medlock SD Rabkin GY Gillespie T Todo, et al. 2000 Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial Gene Ther 7 867 874 10845725 10.1038/sj.gt.3301205 1:CAS:528:DC%2BD3cXjsVKju7Y%3D (Pubitemid 30303584)
36. R Rampling G Cruickshank V Papanastassiou J Nicoll D Hadley D Brennan, et al. 2000 Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma Gene Ther 7 859 866 10845724 10.1038/sj.gt.3301184 1:CAS:528:DC%2BD3cXjsVKju7k%3D (Pubitemid 30303583)
37. U Haberkorn ME Bellemann L Gerlach I Morr H Trojan G Brix, et al. 1998 Uncoupling of 2-fluoro-2-deoxyglucose transport and phosphorylation in rat hepatoma during gene therapy with HSV thymidine kinase Gene Ther 5 880 887 9813658 10.1038/sj.gt.3300679 1:CAS:528:DyaK1cXksFWmtbw%3D (Pubitemid 28371904)
38. AJ Pantuck F Berger A Zisman D Nguyen CL Tso J Matherly, et al. 2002 CL1-SR39: a noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography J Urol 168 1193 1198 12187266 10.1016/S0022-5347(05)64624-1 1:CAS:528:DC%2BD38XmvVWqu7k%3D
39. SS Yaghoubi JR Barrio M Namavari N Satyamurthy ME Phelps HR Herschman, et al. 2005 Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography Cancer Gene Ther 12 329 339 15592447 10.1038/sj.cgt.7700795 1:CAS:528: DC%2BD2MXhtlahsb8%3D (Pubitemid 40315193)
40. M Muzi AM Spence F O'Sullivan DA Mankoff JM Wells JR Grierson, et al. 2006 Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas J Nucl Med 47 1612 1621 17015896 1:CAS:528:DC%2BD28XhtFKjtrbO (Pubitemid 47545026)